Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAibin LiangTongji University

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals glofitamab improves complete responses in refractory DLBCL, indicating safety of bridging CAR T-cell therapy.

Key Points

  • The research aimed to evaluate the efficacy and safety of glofitamab as bridging therapy to CAR T-cell therapy in patients with refractory DLBCL.
  • Retrospective study involving 10 patients with refractory DLBCL treated with glofitamab in Shanghai Tongji Hospital.
  • Patients underwent leukapheresis prior to bridging treatment.
  • Outcomes measured included response rates and safety profiles after treatment.
  • Overall response rate was 80%, with 20% achieving complete responses after glofitamab infusion.
  • Median progression-free survival was 6.5 months.
  • Cytokine release syndrome occurred in 60% of patients, all grade 1.

Cite This Study

Aibin Liang (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d52chttps://doi.org/10.1182/blood-2025-7265
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025 · 1 citations
  2. 2Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma2025
  3. 3Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  4. 4Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort2026
  5. 5TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma2026